Menu
Programme Steering Committee, Advisors and Topic Leaders
Introducing the DIA Europe 2018 Programme Steering Committee
REGULATORY SCIENCE CO-CHAIRS:
Luca Pani
Professor, Department of Psychiatry and Behavioral Sciences, University Of Miami School Of Medicine; Executive Director of Global Medical Innovation NeuroCog, USA
Michelle Rohrer
Global Head of PD Regulatory and Policy
F. Hoffmann-La Roche and Genentech, Switzerland
VALUE & ACCESS CO-CHAIRS:
Jens Grueger
Head of Global Pricing & Market Access
F. Hoffmann-La Roche, Switzerland
A.R. (Ad) Schuurman
Head of International Department
National Health Care Institute (ZIN), Netherlands
TRANSLATIONAL MEDICINE & SCIENCE CHAIR:
Salah-Dine Chibout
Global Head of Discovery & Investigative Safety (DIS)
Novartis Institutes, Switzerland
Program Committee
-
Salah-Dine Chibout • Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
Novartis Pharma AG, Switzerland -
Jens Grueger, PhD • Head Global Pricing & Market Access, Pharma Division
F. Hoffmann-La Roche, Switzerland -
Luca Pani, MD • Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences
University of Miami, United States -
Michelle Rohrer, PhD • Senior Vice President, Global Head of Product Development Regulatory and Policy
Genentech, A Member of the Roche Group, United States -
Vivianne Arencibia • Independent Consultant
Arencibia Quality and Compliance Associates, United States -
Sabine Atzor, MPharm, RPh • Head of EU Regulatory Policies
F. Hoffmann-La Roche Ltd, Switzerland -
Ursula Busse, PhD, MBA • Head of Regulatory Intelligence & Policy
Boehringer Ingelheim, Germany -
João Duarte, MPharm, MSc • Director, Chief of Staff & Regulatory Science
Alexion Pharmaceuticals, France -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Cordula Landgraf, RPh • Head of Networking
Swissmedic, Switzerland -
Francesco Pignatti, MD • Head of Oncology and Hematology
European Medicines Agency, Netherlands -
Bettina Ryll • Chair ESMO Patient Advocates Working Group (PAWG)
Melanoma Patients, Sweden -
Claudine Sapède, PharmD • Director, Global HTA Policy
Novartis Pharma AG, Switzerland -
Ad Schuurman, MBA, MSc • Head of the Business Contact Centre & International Affairs
National Health Care Institute (ZIN), Netherlands -
Indranil Bagchi, PhD, MSc • Senior Vice President and Head, Global Value and Access
Novartis Oncology, United States -
Isabelle de Zegher, DrMed, MD, MS, MSc • Founder
B!Loba, Belgium -
Petra Doerr, PharmD, RPh • Head of Unit Regulation and Safety, Regulation and Prequalification Department
World Health Organization, Switzerland -
Vicki Edwards GBh • Vice President, Pharmacovigilance Excellence and International QPPV
AbbVie, Inc., United Kingdom -
Georgy Genov, MD • Head of Pharmacovigilance Office, Quality and Safety of Medicines Department
European Medicines Agency, Netherlands -
Anthony Humphreys, MPharm • Head of the Regulatory Science and Innovation Task Force
European Medicines Agency, Netherlands -
Merete Joergensen, MBA, MSc • Senior Director, Clinical Transparency
Novo Nordisk A/S, Denmark -
Jordi Llinares Garcia, MS • Head of Research and Innovation
European Medicines Agency, Netherlands -
Manfred Maeder, PhD • Head of Device Development & Commercialization
Novartis, Switzerland -
Thomas Metcalfe, MBA • Data Policy Leader, Personalised Healthcare
F. Hoffmann-La Roche, Switzerland -
Sharon Olmstead • Global Head, Regulatory & Development Policy
Novartis Pharmaceuticals Corporation, United States -
Representative Invited • Merck KGaA, Germany
-
Thomas Senderovitz, DrMed, MD • Senior Vice President, Data Science
NovoNordisk, Denmark -
Representative Invited • European Medicines Agency, Netherlands
